Exponential Progression of Targeted Protein Degradation Drug Discovery

INTRODUCTION

Targeted protein degradation (TPD) has emerged as a transformative therapeutic modality in modern drug discovery. Unlike conventional small-molecule inhibitors, which typically suppress protein function through occupancy-driven mechanisms, TPD technologies exploit the cell’s endogenous protein quality-control machinery to selectively eliminate pathogenic proteins. By inducing proteasomal degradation of target proteins, degraders can achieve catalytic and sustained target removal, potentially overcoming limitations associated with traditional inhibitors.

One of the first leading TPD approaches are PROteolysis TArgeting Chimeras (PROTACs). PROTACs are bifunctional small molecules that induce the selective degradation of disease-associated proteins by recruiting them to an E3 ubiquitin ligase. This interaction promotes ubiquitination of the target protein, leading to its recognition and destruction by the ubiquitin–proteasome system. Unlike conventional inhibitors that temporarily block protein activity, PROTACs eliminate the target protein itself, resulting in more complete and sustained suppression of its biological function. Recently, a clinical level PROTAC, (Vepdegestrant)  was the first in its class to be approved by the FDA for treating cancer.

Beyond PROTACs and molecular glues, the TPD landscape has recently expanded. Lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs and ATTECs), antibody-based degraders, RIBOTACs, and other emerging modalities are enabling the selective removal of membrane proteins, secreted proteins, RNA molecules, and intracellular targets that are inaccessible to conventional proteasome-dependent approaches. These advances are being supported by an expanding understanding of E3 ligase biology, the identification of novel degradation pathways, and the application of artificial intelligence and structure-guided design strategies that facilitate degrader optimization and target selection.

As a result, TPD has attracted significant attention across oncology, immunology, neuroscience, and inflammatory disease research, where many therapeutically relevant proteins have historically been considered difficult or impossible to drug.

RECENT ADVANCES IN PROTACS, MOLECULAR GLUE DEGRADERS AND LYTACS

The First FDA Approval of a PROTAC Drug.

Vepdegestrant (VEPPANU™) represents a landmark achievement in drug discovery as the first PROTAC therapy ever approved by the U.S. FDA for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Unlike conventional inhibitors that merely block protein function, vepdegestrant is a heterobifunctional small molecule designed to induce targeted protein degradation. One end of the molecule binds the estrogen receptor (ERα), while the other recruits an E3 ubiquitin ligase bringing the two proteins into close proximity. This interaction triggers polyubiquitination of ERα, marking it for destruction by the cellular 26S proteasome. The resulting depletion of ER protein leads to cell-cycle arrest and ultimately cancer cell death or growth inhibition in ER-dependent tumors. Clinically, vepdegestrant is administered orally, providing a significant convenience advantage over injectable endocrine therapies. Among patients harboring ESR1 mutations, vepdegestrant demonstrated a statistically significant improvement in progression-free survival (PFS), establishing proof that targeted protein degradation can generate meaningful clinical benefit in patients with endocrine-resistant breast cancer. The approval of vepdegestrant therefore represents not only a new therapeutic option for patients with ESR1-mutated disease but also a major validation of the broader targeted protein degradation field, opening the door for future PROTAC-based therapies against previously difficult-to-drug oncogenic targets.

Expansion of Molecular Glue Degraders

Recent advances in molecular glue degraders (MGDs) have transformed targeted protein degradation into a rapidly expanding drug discovery platform capable of addressing previously “undruggable” proteins. Molecular glues are small molecules that induce or stabilize interactions between an E3 ubiquitin ligase and a target protein, resulting in polyubiquitination and subsequent degradation of the target by the ubiquitin-proteasome system. Unlike PROTACs, which contain separate ligands connected by a linker, molecular glues function as monovalent compounds that remodel protein-protein interaction surfaces to create novel ternary complexes.

At the cellular level, degradation of disease-driving proteins leads to sustained suppression of signaling pathways, transcriptional programs, and oncogenic networks that are often inaccessible to conventional inhibitors. Clinically, molecular glue degraders are being developed for hematologic malignancies, solid tumors, autoimmune disorders, and neurodegenerative diseases. More recently, advances have dramatically accelerated the discovery of new molecular glues. High-throughput phenotypic screening, covalent fragment screening, proximity labeling technologies, and quantitative proteomics have further expanded the repertoire of degradable proteins, revealing opportunities to target transcription factors, RNA-binding proteins, scaffolding proteins, and regulatory proteins that lack conventional enzymatic active sites.

These technological advances have led to the identification of molecular glues capable of degrading oncogenic transcription factors, and other lineage-specific regulatory proteins, opening new therapeutic strategies for cancers driven by aberrant transcriptional programs. Collectively, the convergence of structural biology, computational modeling, and advanced screening technologies has positioned molecular glue degraders as one of the most promising next-generation therapeutic modalities, with the potential to selectively eliminate disease-causing proteins that were previously considered beyond the reach of traditional small-molecule drug discovery.

Progress in Extracellular and Membrane Protein Degradation (LYTACs)

Recent advances in lysosome-targeting chimeras (LYTACs) have expanded the scope of targeted protein degradation beyond the intracellular proteome, creating a new therapeutic modality capable of eliminating extracellular, membrane-bound, and secreted disease-associated proteins. LYTACs are bifunctional molecules composed of a target-binding moiety (typically an antibody, peptide, or small molecule ligand) linked to a lysosome-shuttling ligand that engages endogenous cell-surface lysosomal trafficking receptors. Upon binding both the target protein and the trafficking receptor, the LYTAC induces receptor-mediated endocytosis, directing the target-receptor complex through the endosomal pathway and ultimately to lysosomes where proteolytic degradation occurs.

Unlike ubiquitin-proteasome–based degraders, which require intracellular target engagement and ubiquitination, LYTACs exploit natural lysosomal trafficking mechanisms, enabling degradation of extracellular cytokines, soluble pathogenic proteins, membrane receptors, and immune regulatory molecules.

The therapeutic potential of LYTACs spans oncology, immunology, fibrosis, neurodegenerative disease, and metabolic disorders.  Recent advances in structure-based protein engineering, cryo-electron microscopy, computational modeling, AI-assisted binder optimization, and high-throughput screening technologies have significantly accelerated LYTAC discovery. Collectively, these innovations are transforming targeted protein degradation from an intracellular technology into a comprehensive platform capable of selectively removing disease-causing proteins across the entire cellular microenvironment.

TABLE 1. Comparison of three major TPD modalities

In summary, PROTACs, MGD and LYTACs have unique features, advantages and disadvantages.

• PROTACs: Degrade intracellular enzymes, signaling proteins, kinases, and transcriptional regulators.
• Molecular Glues: Target previously undruggable intracellular proteins, especially transcription factors and regulatory proteins through induced protein-protein interactions.
• LYTACs: Eliminate extracellular proteins, cytokines, immune checkpoints, receptor tyrosine kinases, and secreted disease mediators that cannot be accessed by proteasome-dependent degraders.

PROTACs, molecular glues, and LYTACs form a complementary degradation toolkit capable of targeting disease-causing proteins throughout the intracellular, membrane-associated, and extracellular proteome, substantially expanding the range of therapeutically actionable targets.

NEXT-GENERATION TARGETED DEGRADATION PLATFORMS

Several next-generation targeted degradation platforms have emerged in the last few years that expand the concept of induced proximity beyond PROTACs, molecular glues, and LYTACs. The four most promising approaches are summarized below. All remain in preclinical development but have demonstrated proof-of-concept in cellular and animal models.

TABLE 2. Comparison of Next-Generation Targeted Degradation Platforms

AUTACs (Autophagy-Targeting Chimeras)

AUTACs exploit the cell’s selective autophagy pathway rather than the proteasome. A degradation tag resembling a cellular stress signal is linked to a ligand for the target protein. This induces ubiquitination and recruitment of autophagy receptors, resulting in encapsulation within autophagosomes and delivery to lysosomes. Unlike PROTACs, AUTACs can remove large protein complexes, protein aggregates, and even dysfunctional mitochondria (mitophagy). This makes them particularly attractive for neurodegenerative diseases and mitochondrial disorders.

ATTECs (Autophagosome-Tethering Compounds)

ATTECs represent a more direct autophagy-based strategy. These small molecules simultaneously bind a target protein and a structural component of autophagosomes. By physically tethering the target to forming autophagosomes, ATTECs bypass the need for ubiquitination and E3 ligases. The most advanced studies have focused on degradation of mutant huntingtin protein in Huntington’s disease models, where substantial reductions in aggregate burden and disease phenotypes have been demonstrated in vivo.